| Mgmt Confidence | High confidence in ultra-sensitive detection down to 1-3 parts per million. |
|---|---|
| Demand Visibility | Study recruitment doubled; high interest from pharma partners for clinical trials. |
| Op. Leverage | Ultra-sensitive assay reduces need for multiple blood draws, improving efficiency. |
| Segment Growth | 100% detection in both liver and traditionally difficult lung recurrence sites. |
| New Clients | Collaborations with BC Cancer and potential future pharmaceutical partnerships for trials. |
| Regulatory | MRD results currently for research; AJCC staging may eventually include CTDNA. |
| Commentary | Ultra-sensitive detection provides six months extra lead time for clinical intervention. |
| New Launches | NeXT Personal assay utilizing whole genome sequencing and 1,800 personalized variants. |
Growth
96% pre-surgical sensitivity; 83.9% sensitivity in MRD window; 176-day lead time over standard imaging.
Outlook
Study continues to recruit with twice as many patients; updates and publication pending.
Risks
Clinical utility remains a research question; lack of head-to-head data against competitors; reimbursement challenges in Canada.
The company's earnings call, NASDAQ: PSNL, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Personalis, Inc.: key numbers
- Share price
- $14.80Close, Nov 16
- Market cap
- $1.6B
- Shares outstanding
- 108.4MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Personalis, Inc.
All →Personalis CEO Christopher M. Hall Sells $462K of Stock
Christopher M. Hall, CEO, sold 29,112 shares of Personalis, Inc. at $15.87 a share, worth $462K in total on Nov 3, 2026. Shares held after the trade: 199,415 (-12.7%).
- Value
- $462K
- Shares
- 29,112
- Price
- $15.87
- Role
- CEO
- Holding change
- -12.7%
- Trade date
- Nov 3, 2026
Personalis Financial Results
Personalis reported Q3 2026 total revenue of $25.6 million, a significant increase from $14.5 million in the prior year, driven by growth in clinical test volume and population sequencing. The company ended the quarter with $190.6 million in cash and noted its pending merger with Tempus AI. Due to the pending acquisition, the company is no longer providing forward-looking financial guidance.
“These results reflect the strength of our team’s execution and commitment to helping transform the active management of cancer through more informed care. Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians, and biopharma partners.”
Chris Hall, Chief Executive Officer of Personalis
Personalis Q3 2026 Results: Net Loss of $33.8M, Loss Widens
Personalis, Inc. has entered into a definitive merger agreement to be acquired by Tempus AI, Inc. The company continues to report a history of losses and maintains significant customer concentration with Moderna, the VA MVP, and Merck while focusing on its partner-centric strategy for cancer testing services.
- Key figure
- Net loss $33.8M
Personalis M&A Deal with Tempus AI, Inc.
Personalis announced the expiration of the Hart-Scott-Rodino (HSR) Act waiting period regarding its pending acquisition by Tempus AI, Inc. The expiration of the antitrust waiting period satisfies a key closing condition for the merger, which was originally announced on July 20, 2026. The transaction remains subject to approval by Personalis stockholders and other customary closing conditions.
- Counterparty
- Tempus AI, Inc.